Anavex Life Sciences Corp (AVXL)

[JWC3]

So from that it appears that the ANAVEX RTT data, if it shows reasonable efficacy, could lead to a quick approval! Quick, because of Fast Track and Rare Pediatric Disease and Orphan Designations. This would be for 18+yo Rett Syndrome patients, of which there are about 5000 in the US. This is incredible good. So our revenue will begin to trickle into ANAVEX and we will receive the $80M voucher.

In addition, the A 2-73 would now be registered as an approved pharmaceutical. That will allow the Australian TGA to easily and quickly grant Provisional Approval (PA) for A 2-73 for Dementia! This in turn will increase revenue by a good amount. It will also prompt the ROW to grant PA. Fantastic! When this gets rolling so will revenue. We already know that revenue for ALZHEIMER’S will be “ from $13B to $67B “ per year! That is from $1B to $5B revenue per month! This gives a MC from $60B to $300B. So a share of AVXL will be worth from $998 to $4991. This will happen within a year or two. Also this is as a result of delivering a therapeutic treatment for ALZHEIMER’S. We also know that ANAVEX will provide therapies for many indications and used prophylactically. So that will at least triple its value. In addition, ANAVEX has at least 3 viable new drugs in its pipeline which should easily double its value. This is ALL VERY PROBABLE.

Why is the AVXL stock price at $4.80?